Novartis
Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug
October 16, 2018Manufacturing and Production Bayer, CCG, NHS, Novartis, avastin, wet AMD
Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning …
Novartis’ sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2
October 10, 2018Research and Development Novartis, crizanlizumab, pharma, sickle cell disease
Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …
Top Ten most popular articles on Pharmafile.com this week
October 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Jannsen, NHS, Novartis, Novo Nordisk, dementia, top 10
As September came to a close and October began the UK was hit hard in the headlines after American firm …
Novartis forge deal with Boston Pharmaceuticals in effort against AMR
October 3, 2018Research and Development AMR, Antibiotics, Boston Pharmaceuticals, Novartis, US
Swiss multinational Novartis have entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel …
20 year old man died after leukaemia cell was accidently mixed into CAR T therapy
October 2, 2018Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology
A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …
Top Ten most popular articles on Pharmafile.com this week
September 28, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, NHS, Novartis, pharma
Life expectancy was a key topic this week, as it emerged that growth has stalled and even fallen in areas …
Novartis strike $40m deal with Chinese firm Cellular Biomedicine
September 28, 2018Medical Communications CAR T, CAR-T, China, Kymriah, Novartis, cellular biomedicine, prc
Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in …
Novartis joins forces with GARDP for better, accessible infectious disease treatments in the developing world
September 27, 2018Research and Development, Sales and Marketing GARDP, Novartis, infectious disease, pharma
Novartis has partnered up with the Global Antibiotic Research & Development Partnership (GARDP) to push for faster development and wider …
Novartis cuts more than 2500 jobs in Switzerland and the UK
September 25, 2018Manufacturing and Production Basel, Jobs, Novartis, Switzerland, grimsby, manufacturing
Swiss multinational Novartis are set to cut thousands of jobs across Europe in an effort to boost profitability. The move …
Courts back NHS in fight against Novartis and Bayer
September 24, 2018Sales and Marketing Bayer, Eylea, NHS, Novartis, avastin, ludentis
The NHS has won a court case against multinational pharmaceutical firms Novartis and Bayer, after the companies sought to block …
Top Ten most popular articles on Pharmafile.com this week
September 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Novartis, Novo Nordisk, Senate, UCB, manufacturing, opioid crisis, top 10
Manufacturing took a hit this week as Novo Nordisk announced the loss of 400 jobs while Novartis made the move …
NICE rejects CAR-T therapy Kymriah for DLBCL in adults
September 19, 2018Research and Development CAR T, CAR-T, Kymriah, NICE, Novartis, leukaemia
The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …
Novartis to relocate Arnhem operations to Amsterdam, 400 jobs affected
September 19, 2018Manufacturing and Production, Research and Development Netherlands, Novartis, amsterdam, pahrma, pharma
Novartis has announced it is to relocate its operations in Arnhem in the Netherlands to the capital city of Amsterdam, …
NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma
September 17, 2018Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma
NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …
Pfizer, Novartis, MSD, Novo and GSK halt operations in wake of Hurricane Florence
September 14, 2018Medical Communications GSK, Hurricane Florence, MSD, Novartis, Novo Nordisk, Pfizer, pharma
As Hurricane Florence begins to breach the Southeast Coast, major pharma firms have announced they are enacting contingency plans, including …
Latest content
FibroFind appoints Lee Borthwick as CEO
